TIL Profile
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cutting-edge therapies for cancer treatment. The company specializes in the advancement of cell-based therapies, particularly those utilizing autologous tumor-infiltrating lymphocytes (TILs). These therapies are designed to harness the body's own immune system to target and eliminate cancer cells more effectively.
Instil Bio's pipeline includes several promising TIL product candidates, with the lead candidate, ITIL-168, being developed for a range of malignancies. These include melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. ITIL-168 aims to improve outcomes by leveraging TILs to specifically target and destroy cancer cells in these various tumor types.
Another notable candidate, ITIL-306, is engineered to recognize the folate receptor alpha (FOLR1) and is being investigated for its efficacy in treating cancers that express this receptor. The potential indications for ITIL-306 include gynecological cancers, non-small cell lung cancer, and renal cancer, among others. This product is part of Instil Bio’s broader strategy to expand the applicability of TIL therapy to additional cancer types and patient populations.
Founded in 2018 and headquartered in Dallas, Texas, Instil Bio is at the forefront of innovation in cell therapy. The company is dedicated to transforming the landscape of cancer treatment through its advanced therapeutic approaches and cutting-edge research. Its mission is to develop and deliver effective, personalized treatments to improve the lives of cancer patients worldwide.
|
